

Scoring over Invasive Candidiasis with Candida score

DrBaishali Chakraborty¹, DrDibyendu Banerjee², DrAnkit Chakraborty³,
DrBanya Chakraborty⁴

¹(Department of Microbiology, Dr B C Roy Postgraduate Institute of Pediatric Sciences, West Bengal University of Health Sciences, India)

²(Corresponding Author-Department of Microbiology, Calcutta National Medical College, West Bengal University of Health Sciences, India)

³(Department of Microbiology, Calcutta Medical College, West Bengal University of Health Sciences, India)

⁴(Department of Microbiology, Calcutta School of Tropical Medicine, West Bengal University of Health Sciences, India)

Correspondence to: Dr Dibyendu Banerjee

Abstract:Introduction: Invasive Fungal Infection (IFI) is a critical event in clinical scenario, and Invasive Candidiasis is chief among them, accounting for 70-90% of all IFIs. In 2006, Candida score was developed to predict this life-threatening infection. This study makes a similar attempt to identify invasive candidiasis and measure the candida score in the present scenario of a tertiary care hospital, as well as to detect the prevalence of *Candida albicans* and non-*albicans* species.

Materials and methods: This study was undertaken on patients admitted in Intensive care unit of a tertiary medical care hospital. Specimens obtained from different sites were taken to laboratory to culture in Blood agar media. If there was growth in Blood agar – Gram staining was done and if *Candida* was found, it was sub-cultured in Chromogenic agar plates to identify species.

Result: Out of 129 samples, 11 were positive for *Candida* (8.49%). Out of 11 *Candida* isolates, only one was *Candida albicans*, others being non-*albicans* *Candida*. Most of them were *Candida krusei*.

Discussion: None of the cases touched the Candida score of 2.5, a predictor of invasive candidiasis. This was a great finding in itself, and was in stark contrast with findings from many institutions. However, our findings also collaborated with them in that maximum clinical isolates were non-*albicans* type. But here maximum isolates were *C. krusei*, although most clinical isolates are reported to be *C. tropicalis* from Asian subcontinents including India, and *C. glabrata* from Western countries.

Keywords: *Candida* score, Invasive candidiasis, Speciation

Date of Submission: 14-11-2018

Date of acceptance: 29-11-2018

I. Introduction

Ability to predict a critical event is one of the most important skills of critical care management. Invasive fungal infections (IFI) is one such critical event. Invasive Candidiasis stands as the fourth most common cause of nosocomial septicemia and leading cause amongst invasive mycosis in non-neutropenic critically ill patients. [1] Whatever limited data is available of IFIs in Asian Countries – a very high incidence is predicted. Invasive Candidiasis, which accounts for 70-90% of all IFIs, is associated with higher mortality rates, estimates varying from 38-80%. However unfortunately enough, early diagnosis remains a challenge and criteria for starting empirical antifungal therapy in CCU patients are poorly defined. In 2006, a Spanish group using database of a candidiasis project identified four predictors of proven invasive candidiasis based on which Leon et al developed the ‘Candida score’. It was a cohort study of 1699 critically ill CCU patients. Authors reported a sensitivity of 81% and specificity of 74% with a cut off value 2.5. [2] This study makes a similar attempt to identify invasive candidiasis and measure the candida score in the present scenario of a tertiary care hospital, as well as to detect the prevalence of *Candida albicans* and non-*Candida albicans* species. Thus it may be used to guide the clinicians to differentiate patients who shall really benefit from early antifungal therapy and ensure its judicious use to prevent inadvertent high cost and in future emergence of resistance in a developing country like ours.

II. Material And Methods

Type of study: Descriptive observational type of epidemiological study.

Study design: Cross sectional study.

Duration of study: 2 months, from 27th June, 2016 to 27th August, 2016.

Study population: 40 CCU admitted patients during the course of the study.

Choice of subjects: By randomly sampling those who fulfilled the inclusion criteria.

Selection of control: No control as it will be a descriptive study.

Procedure:

Samples were collected from the non neutropenic patients with minimum 7 days of hospital stay. Specimens were obtained from urine, tracheal aspirate, skin, oral mucosa, wounds, and drains from surgical sites. Urine was collected in a sterile wide mouthed container with screw cap tops, tracheal aspirates were taken from intubated patients with the help of sucker and for the other samples sterile swabs were used. Samples were then taken to laboratory to culture in Blood agar media following standard techniques. Plates were incubated overnight at 37 degree Celsius. If there is growth in Blood agar – Gram staining was done and if *Candida* was found, it was sub-cultured in Chromogenic agar plates (HiCrome*Candida* Differential Agar Media, M1297A) and incubated for 48 hours to identify species. The species identification was done by the different colours produced by the different *Candida* species, according to the HIMEDIA recommendations which are following:

CANDIDA SPECIES	COLOUR OF COLONY
<i>C. albicans</i>	Light green
<i>C. glabrata</i>	Cream to White
<i>C. krusei</i>	Purple
<i>C. tropicalis</i>	Blue

Then Candida score was determined.

Ethical Issues: The required permission to conduct the study was given by the Institutional Ethics Committee.

III. Results

Table no 1:Number of *Candida* positive cultures isolated from the samples collected from different sites:

SAMPLES	NO. OF SAMPLES	CANDIDA POSITIVITY
Urine	38	8
Oral swabs	40	3
Skin swabs	39	0
Tracheal aspirate	7	0
Wound swabs	1	0
Surgical drain	4	0

Comments:Out of 129 samples collected from 40 patients, 11 samples are positive for *Candida* (8.52%). Most of the samples yielding to *Candida* production are urine samples, rest being oral swabs.

Table no2:Number of *Candida albicans*& non-*albicans* species isolated from the samples.

CANDIDA SPECIES TYPE	FINDINGS	
	NO.	%
Albicans	1	9.09
Non-Albicans	10	90.90
Total	11	100

Comments: Non-*albicans* comprise of >90% of total *Candida* isolated.

Table no3:Number of different *Candida* species isolated from the samples collected from different sites:

SAMPLES	weeks.			
	CANDIDA ALBICANS	CANDIDA TROPICALIS	CANDIDA KRUSEI	CANDIDA GLABRATA
Urine	1	2	4	1
Oral swabs	0	0	3	0
Skin swabs	0	0	0	0
Tracheal aspirate	0	0	0	0
Wound swabs	0	0	0	0
Surgical drain	0	0	0	0

Comments: Among the non-*albicans Candida* isolated, *Candida krusei* amounts for most, followed by *Candida tropicalis* and *Candida glabrata*, the last one being same in number as *Candida albicans*




Figure 1: Different *Candida* species identified in *Candida* Chrome Agar.

IV. Discussion

Two main factors predispose to infections with *Candida* spp.: colonization of skin and mucous membrane with *Candida*, and alteration of natural host barriers (wounds, surgery, and insertion of indwelling intravascular and urinary catheters). Colonization with *Candida* is also induced by profound alteration of the endogenous flora resulting from prolonged broad-spectrum antibiotic therapy. Other risk factors include loss of integrity of skin and mucosal barriers – surgery (especially of the abdominal compartment), total parenteral nutrition, acute renal failure, haemodialysis and treatment with immunosuppressive agents.[3] In the past, researchers have tried to predict infections by measuring the *Candida* colonization of distinct body sites (upper respiratory or stomach samples, urine and wound swabs) divided by the number of sites tested, which became known as the colonization index (CI). Although the negative predictive value was 100%, the positive predictive value for candidemia was relatively low (66%) and could only be improved if the CI was corrected by quantitative culture. [4] In 2006, ‘Candida Score’ was developed for predicting *Candida* infection in non-neutropenic critically ill patients. External validation of this study has been done independently. Leonetal in 2009 assessed the usefulness of Candida Score in 1107 non neutropenic adult ICU patients in multicentre study conducted in Spain, France and Argentina. For identifying high risk group for invasive Candidiasis, a cut off value of >3 was taken. They reported an area under curve (AUC) of 0.774, positive predictive value of 13.8% and negative predictive value of 97.7%. [5] This study was conducted in an apex institute where the patient admission flow is massive (including CCU) as the institute itself ranks among one of the topmost in the country. In this era of worldwide threat known as HAI (Health care associated infections), the findings here are no less a reason to bear pride. Invasive candidiasis as we know is of very high incidence among HAI and is a life threatening condition. Here, in this study, none of the cases crossed that dangerous mark, indicating this institution to set an exemplary milestone for other hospitals in controlling HAI. Thus our findings stand in stark contrast against that of the world wide scenario. Magnitude of the problem of candidemia is such that it possesses an international threat. International data at a glance is as follows: in USA rate of candidemia amounts to 0.8/1000 discharges in Europe 0.2 – 0.5/1000 discharges and in Australia 0.09-0.36/1000 admissions , whereas Indian data indicates a 20-30 times higher rate compared to developed world : 1-12/1000 admissions . [6,7,8] Thus, incidences of candidiasis have been found to range from 0.39/1000 to 14.2/1000 on discharge or admission. [9,10] Not only that, among ICU patients, the incidence were higher, around 2.2/1000 to 41/1000 on discharge or admission. [11] It is to be noted that there has been a shift towards non-albicans *Candida* infections in HAI in past two decades. [12] This is where our study comes out with similar findings. *Candida glabrata* remains the most common isolated species in Western countries whereas in Asia, *Candida glabrata* remains low (11% or less) & *Candida tropicalis* is the most common *Candida* non-albicans species in Hong-Kong, Singapore, India. [13] However, in spite of getting majority growth as non-albicans *Candida*, our commonest findings was *Candida krusei*. This study was of a descriptive (observational) nature. If there were any positive findings, it would have been followed up with an analytical type of study, the scope of which is null & void in this case. The study duration was restricted to 2 months, thus limiting samples collection from only 40 patients who fulfilled all the inclusion criteria. In future, this study should be carried out in all the ICUs of major and minor hospitals for sufficient period to evaluate the actual scenario if one wants to keep invasive Candidiasis at bay.

References

- [1]. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. *Clin Infect Dis* 1999; 29:239–44.
- [2]. Leon C, Ruiz-Santana S, Saavedra P, et al. “A bedside scoring system (“Candida score”) for early antifungal treatment in non-neutropenic critically ill patients with Candida colonization.” *Crit Care Med*. Mar 2006; 34(3):730-737.
- [3]. Dimopoulos G, Karabinis A, Samonis G, Falagas ME. “Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study.” *Eur J Clin Microbiol Infect Dis*. 2007; 26:377-384
- [4]. Pittet D, Monod M, Suter PM et al. “Candida colonization and subsequent infections in critically ill surgical patients.” *Ann Surg*. 1994; 220:751-58.
- [5]. Leon C, Ruiz-Santana S, Saavedra P, Galván B, Blanco A, Castro C, et al. Cava Study Group. “Usefulness of the Candida scores for discriminating between Candida colonization and invasive Candidiasis in non-neutropenic critically ill patients: a prospective multicentre study.” *Crit Care Med*. 2009; 37:1624-33.
- [6]. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. *J Clin Microbiol*. 2004; 42(4):1519-27.
- [7]. Arendrup MC, Fuursted K, Gahrn-Hansen Bente, Jensen IM et al. Seminal surveillance of Fungemia in Denmark: Notably high rates of Fungemia and numbers of isolates with reduced Azole susceptibility. *J Clin Microbiol*. 2005; 43(9):4434-40.
- [8]. Chakraborty A, Chatterjee SS, Shivaprakash MR. Overview of opportunistic fungal infections in India. *Jpn J Med Mycol*. 2011; 49:165-72.
- [9]. Liu CY, Liao CH, Chen YC, Chang SC. “Changing epidemiology of nosocomial blood stream infection in 11 teaching hospitals in Taiwan between 1993 and 2006.” *J. Microbiol. Immuno. Infect*. 2010; 43: 416-29.
- [10]. Verma AK, Prasad KN, Sing M, et al. “Candidemia in patients of a tertiary health care hospital from North India.” *Indian J. Med. Res*. 2003; 117: 122-28.
- [11]. Horassan ES, Ersoz G, Goksu M, et al. “Increase in Candida parapsilosis fungemia in critical care units, a 6 years study”. *Mycopathologia* 2010; 170: 263-68.
- [12]. Pfaller MA, Diekema DJ. “Epidemiology of invasive Candidiasis: a persistent public health problem.” *Clin Microbiol Rev*. 2007; 20:133-163.
- [13]. Hunj CC, Chen YC, Chang SC, Hsier WC. “Nosocomial Candidemia in a university hospital in Taiwan. *J. Forms Med. Assoc*. 1996; 95: 19-28.

DrBaishaliChakraborty., “Scoring over Invasive Candidiasis with Candida score.” IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), vol. 17, no. 11, 2018, pp58-61.